Stephanie L McFall1, David W Smith. 1. University of Texas School of Public Health, Division of Health Promotion and Behavioral Sciences, San Antonio Regional Campus, 8550 Datapoint Dr., Ste. 200, San Antonio, TX 78229, USA. Stephanie.L.McFall@uth.tmc.edu
Abstract
OBJECTIVES: We obtained population estimates of the prevalence of lack of diagnostic follow-up after an abnormal prostate-specific antigen (PSA) result and assessed the role of sociodemographic, access, and risk perception factors on follow-up of abnormal tests. METHODS: We used data from the 2000 National Health Interview Survey cancer control supplement. For 3,310 men aged 40 or older with a PSA test, 463 men reported an abnormal PSA test. Outcomes were abnormal PSA and lack of diagnostic follow-up in the latter group. Covariates for logistic regression included sociodemographic variables (age, race/ethnicity, and education), access to care (health insurance and usual source), and risk of cancer (family history and perceived risk). Survey analysis procedures accounted for the complex survey design. RESULTS: Abnormal PSA results were associated with age, family history, and perceived risk of cancer. Approximately 15% of men with abnormal PSA tests reported no follow-up. The estimated number was 423,549 (95% confidence interval [CI] 317,755, 529,343). No follow-up was more likely in Hispanic men (odds ratio [OR] = 2.21, 95% CI 1.04, 4.70) and men without insurance (OR=6.56, 95% CI 2.02, 21.29), but less likely in men with a family history of prostate cancer or higher perceived risk of cancer. CONCLUSIONS: Substantial numbers of men had no follow-up of abnormal PSA tests. Primary care physicians should assess continuity of care following abnormal PSA results. Data about prostate cancer screening and follow-up are needed to support clinical and policy decisions.
OBJECTIVES: We obtained population estimates of the prevalence of lack of diagnostic follow-up after an abnormal prostate-specific antigen (PSA) result and assessed the role of sociodemographic, access, and risk perception factors on follow-up of abnormal tests. METHODS: We used data from the 2000 National Health Interview Survey cancer control supplement. For 3,310 men aged 40 or older with a PSA test, 463 men reported an abnormal PSA test. Outcomes were abnormal PSA and lack of diagnostic follow-up in the latter group. Covariates for logistic regression included sociodemographic variables (age, race/ethnicity, and education), access to care (health insurance and usual source), and risk of cancer (family history and perceived risk). Survey analysis procedures accounted for the complex survey design. RESULTS: Abnormal PSA results were associated with age, family history, and perceived risk of cancer. Approximately 15% of men with abnormal PSA tests reported no follow-up. The estimated number was 423,549 (95% confidence interval [CI] 317,755, 529,343). No follow-up was more likely in Hispanic men (odds ratio [OR] = 2.21, 95% CI 1.04, 4.70) and men without insurance (OR=6.56, 95% CI 2.02, 21.29), but less likely in men with a family history of prostate cancer or higher perceived risk of cancer. CONCLUSIONS: Substantial numbers of men had no follow-up of abnormal PSA tests. Primary care physicians should assess continuity of care following abnormal PSA results. Data about prostate cancer screening and follow-up are needed to support clinical and policy decisions.
Authors: Lucy A Brindle; Steven E Oliver; Daniel Dedman; Jenny L Donovan; David E Neal; Freddie C Hamdy; Janet A Lane; Tim J Peters Journal: BJU Int Date: 2006-10 Impact factor: 5.588
Authors: J L Stanford; Z Feng; A S Hamilton; F D Gilliland; R A Stephenson; J W Eley; P C Albertsen; L C Harlan; A L Potosky Journal: JAMA Date: 2000-01-19 Impact factor: 56.272
Authors: Mona Saraiya; Benny J Kottiri; Steven Leadbetter; Don Blackman; Trevor Thompson; Matthew T McKenna; Fred L Stallings Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-09 Impact factor: 4.254
Authors: Gerald L Andriole; David L Levin; E David Crawford; Edward P Gelmann; Paul F Pinsky; David Chia; Barnett S Kramer; Douglas Reding; Timothy R Church; Robert L Grubb; Grant Izmirlian; Lawrence R Ragard; Jonathan D Clapp; Philip C Prorok; John K Gohagan Journal: J Natl Cancer Inst Date: 2005-03-16 Impact factor: 13.506
Authors: Daniel R Murphy; Louis Wu; Eric J Thomas; Samuel N Forjuoh; Ashley N D Meyer; Hardeep Singh Journal: J Clin Oncol Date: 2015-08-24 Impact factor: 44.544